This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shaked, Y. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Shaked, Y. Articles by Kerbel, R. S.

Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy

Department of Molecular and Cellular Biology, Sunnybrook and Women's College Health Sciences Centre and the Department of Medical Biophysics, University of Toronto, Ontario, Canada

Requests for reprints: Robert S. Kerbel, Molecular and Cellular Biology Research, Room S-217, Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-5711; Fax: 416-480-5884; E-mail: kerbel{at}srcl.sunnybrook.utoronto.ca.

Metronomic chemotherapy refers to the close, regular administration of comparatively low doses of cytotoxic drugs, with minimal or no drug-free breaks, over prolonged periods. It is thought to have an antiangiogenic basis. However, whereas surprisingly durable and potent tumor responses have been observed in a number of preclinical tumor models, relapses usually eventually occur using this type of treatment strategy. We therefore decided to test modified metronomic chemotherapy regimens that might significantly delay such relapses, but still maintain modest and acceptable toxicity profiles. Here, we show that repeated administration of bolus doses (BDs) of cyclophosphamide every 3 or 6 weeks, combined with a daily oral low-dose metronomic (LDM) regimen (20 mg/kg/d cyclophosphamide), improves efficacy and significantly delays progression of transplanted PC-3 human prostate cancer xenografts, syngeneic transplanted EMT-6 breast tumors, and "spontaneous" murine erythroleukemia. Efficacy was superior whereas toxicity was mild and comparable to the LDM regimen, the latter assessed by body weight, neutrophil, lymphocyte, and total white blood counts. Antiangiogenic activity, measured by reduction in circulating endothelial precursor cells, revealed that the greatest degree of suppression occurred using the combination treatment. Overall, our results indicate that the administration of intermittent BD combined with chronic oral LDM cyclophosphamide is a potent treatment regimen for controlling tumor growth, which has a low toxicity profile, over prolonged periods of time.

This article has been cited by other articles:

				G. Francia, U. Emmenegger, C. R. Lee, Y. Shaked, C. Folkins, M. Mossoba, J. A. Medin, S. Man, Z. Zhu, L. Witte, et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using {beta}-human choriogonadotropin secreting tumor cell lines Mol. Cancer Ther., October 1, 2008; 7(10): 3452 - 3459. [Abstract] [Full Text] [PDF]

				W. Cruz-Munoz, S. Man, P. Xu, and R. S. Kerbel Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis Cancer Res., June 15, 2008; 68(12): 4500 - 4505. [Abstract] [Full Text] [PDF]

				J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]

				H. Zhong, B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth Clin. Cancer Res., September 15, 2007; 13(18): 5455 - 5462. [Abstract] [Full Text] [PDF]

				C. Folkins, S. Man, P. Xu, Y. Shaked, D. J. Hicklin, and R. S. Kerbel Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors Cancer Res., April 15, 2007; 67(8): 3560 - 3564. [Abstract] [Full Text] [PDF]

				Q. Zhou, P. Guo, X. Wang, S. Nuthalapati, and J. M. Gallo Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 265 - 275. [Abstract] [Full Text] [PDF]

				A. Suvannasankha, C. Fausel, B. E. Juliar, C. T. Yiannoutsos, W. B. Fisher, R. H. Ansari, L. L. Wood, G. G. Smith, L. D. Cripe, and R. Abonour Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21 Oncologist, January 1, 2007; 12(1): 99 - 106. [Abstract] [Full Text] [PDF]

				Y. Shaked, A. Ciarrocchi, M. Franco, C. R. Lee, S. Man, A. M. Cheung, D. J. Hicklin, D. Chaplin, F. S. Foster, R. Benezra, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, September 22, 2006; 313(5794): 1785 - 1787. [Abstract] [Full Text] [PDF]

				D. G. Duda Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res., April 15, 2006; 66(8): 3967 - 3970. [Abstract] [Full Text] [PDF]

				R. Munoz, S. Man, Y. Shaked, C. R. Lee, J. Wong, G. Francia, and R. S. Kerbel Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. Cancer Res., April 1, 2006; 66(7): 3386 - 3391. [Abstract] [Full Text] [PDF]

				U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia Cancer Res., February 1, 2006; 66(3): 1664 - 1674. [Abstract] [Full Text] [PDF]